Darolutamide is an androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer. This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
- Mechanism
- Curator reviewed · 7 references
The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than apalutamide and enzalutamide, which are other androgen receptor antagonists.
Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time.
- Primary indication
- Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), either as monotherapy or in combination with docetaxel.Curator reviewed · 3 structured indications
- Formula / weight
- C19H19ClN6O2 · 398.85 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2019 · European Union, 2020
- Code names
- BAY-1841788 · ODM-201
- Brand names
Resolves to
BLIJXOOIHRSQRB-PXYINDEMSA-NSMILESC[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)OWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Darolutamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account